Catherine (for John Wolleben)'s questions to Mirum Pharmaceuticals Inc (MIRM) leadership • Q3 2024
Question
Catherine, on behalf of John Wolleben, asked for an update on the ex-U.S. global expansion for LIVMARLI and for any revised views on the U.S. PFIC launch, given its strong quarterly performance.
Answer
President and COO Peter Radovich noted that LIVMARLI now has pricing and reimbursement for Alagille syndrome in the four major EU markets and continues to see growth from distributor partners. He mentioned the PFIC approval in Europe is recent and sales will likely materialize in mid-to-late 2025. CEO Christopher Peetz added that the strong Q3 PFIC result was partly due to a pull-forward of reimbursement, making it a particularly strong quarter.